News & Updates
Filter by Specialty:
Do bDMARDs prevent osteoporotic fractures in RA patients?
Use of biological disease-modifying antirheumatic drugs (bDMARDs) appears to have no benefit in the prevention of osteoporotic fractures among patients with rheumatoid arthritis (RA), according to the results of a recent study.
Do bDMARDs prevent osteoporotic fractures in RA patients?
01 Jul 2022
Baricitinib delays, lowers frequency of flares in JIA
In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.
Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
20 Jun 2022
Change in serum marker levels tied to outcomes of RA-related interstitial lung disease
In rheumatoid arthritis-related interstitial lung disease (RA-ILD), change over time in the levels of serum proteins, such as matrix metallopeptidase 13 (MMP13) and C-X-C motif ligand chemokine 11 (CXCL11), predict clinical outcomes, a recent study has found. The same is true for baseline clinical factors such as patient age and rheumatoid factor.
Change in serum marker levels tied to outcomes of RA-related interstitial lung disease
19 Jun 2022
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
18 Jun 2022
Antihistamines potentially beneficial for knee OA
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
Antihistamines potentially beneficial for knee OA
17 Jun 2022
Familiarity with EuroLupus dosing for cSLE remains low despite uptick in use
Paediatric specialists now use low-dose EuroLupus cyclophosphamide (CYC) more than they did a decade ago in the treatment of childhood-onset systemic lupus erythematosus (cSLE), reports a study in North America. However, familiarity with EuroLupus dosing is still low.
